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Key Messages
1. Deletion of the 3’end of the 
hepatitis B virus X gene 
(HBx) was frequently detected 
in clinical hepatocellular 
carcinoma (HCC) samples.
2. In vivo animal tumour xenograft 
experiments demonstrated the 
tumourigenic ability of the 
C-terminal truncated HBx.
3. cDNA microarray study 
suggested that the C-terminal 
truncated HBx played a 
critical role in the HCC 
development via activation of 
cell proliferation and inhibition 
of apoptosis.
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Introduction
Hepatocellular carcinoma (HCC) has been the second commonest cancer in both 
Hong Kong and China since 1990s. Its overall 5-year survival rate worldwide 
is about 3%, mainly because of late diagnosis. Although the precise molecular 
switch that triggers HCC development remains elusive, the aetiological 
association between hepatitis B virus (HBV) infection and hepatocarcinogenesis 
has been established.1 The relative risk of HCC in HBV carriers is 10-fold higher 
than in non-carriers, but only a small percentage of HBV carriers develop HCC. 
 One important clue has been derived from the Hepatitis B virus X protein 
(HBx), which is one of the four proteins encoded by HBV. Previous studies from 
our group and others have shown that integration of HBV is detected in 80 to 
90% of the host genome of HBV-infected HCC cases, and often results in the 
C-terminal deletion of the protein HBx.2 Thus, we speculated that truncated HBx 
may play a role in HCC development. 
Frequent C-terminal truncation of hepatitis B virus X protein in 
hepatitis B virus–related hepatocellular carcinoma
By screening HCC tissue using a microarray containing 194 pairs of HCCs and 
their matched non-tumour liver tissues, C-terminal truncated HBx was frequently 
observed in HBV-related HCC tissues. In order to investigate the expression 
pattern of HBx in HCCs, two antibodies (Ab1 and Ab2) were generated. Their 
antigen position is shown in Fig. 1a. The antibodies Ab1 and Ab2 can recognise 
the full-length HBx, whereas the Ab2 cannot bind to the C-terminal truncated 
HBx. Immunohistochemistry results showed that the C-terminal truncated HBx 
was detected in 88/111 (79.3%) HCC tissues, whereas full-length HBx was 
observed in all 111 non-tumour liver tissues, but only in 23/111 (20.7%) of HCC 
tissues. The corresponding deletion of 3’ within the X gene was further confirmed 
by polymerase chain reaction (PCR) analysis on 20 HCC cases using five pairs of 
primers encompassing the X gene (Figs. 1b and 1c). 
C-terminal truncated HBx enhanced tumour development
We cloned and constructed mammalian expression vectors for ectopic expression 
of full-length HBx (X2) and C-terminal truncated HBx (X1) in human liver cell 
lines HepG2 and MIHA. Stable X1-expressing (HepG2-X1 and MIHA-X1) and 
X2-expressing (HepG2-X2 and MIHA-X2) cell lines were established and tested 
for their oncogenic ability. MIHA-X1 grew much faster than MIHA-X2 and 
MIHA-P. The colony formation in soft agar was 10-fold higher in MIHA-X1 
than in MIHA-X2 and MIHA-P (P<0.001, Student’s t test). Tumour xenograft 
experiment was performed in nude mice to study the tumourigenicity of X1- and 
X2-expressing cells. Tumour formation in nude mice was observed in 7/10 and 
1/10 of nude mice injected with MIHA-X1 and MIHA-X2 cells, respectively. 
To study the role of HBx in cell apoptosis, a TUNEL assay was employed to 
compare apoptotic frequencies among X1- and X2-expression cells, as well 
as vector-transfected mock control cells. Apoptotic frequencies were similar 
between X1-expression and vector-transfected cells. However, the apoptotic 
frequency in X2-expression cells was significantly higher than in X1-expression 
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or vector-transfected cells (P<0.001, Student’s t test). The 
results are summarised in Fig 2.
cDNA microarray analysis pinpointed key 
molecules involved in the process
Using a cDNA microarray analysis, we identified 
the gene signatures contributing to either full-length 
HBx inducing apoptosis or C-terminal truncated HBx 
promoting tumourigenicity. Of 12 000 human genes used 
to compare gene expression profiles between HepG2-X1 
and HepG2-X2, 59 genes with significant changes were 
identified, including 38 genes up-regulated by X1 and 21 
genes up-regulated by X2. The most relevant and interesting 
finding was that genes up-regulated by X1 gene have 
known functions either promoting proliferation (TFDP1, 
Fig 1. Detection of C-terminal truncation of hepatitis B X protein (HBx) in primary hepatocellular carcinoma (HCC)
(a) Recognition sites of two anti-HBx antibodies (Ab1 and Ab2) on HBx. (b) Polymerase chain reaction (PCR) amplification fragments by 
five pairs of primers used for detecting 3’-end deletion of X gene. (c) Summary of truncation frequencies in HCC/non-tumour pairs in 
different regions of HBx
Fig 2. Truncated-X enhanced tumourigenicity
Ectopic expression of X1 and X2 were established in HepG2 and MIHA cells by stable transfections. Ectopic expression of X1 dramatically 
increased cell growth and colony formation rates, whereas overexpressing X2 inhibited cell growth and induced apoptosis. MIHA-X1 
cells were able to promote tumourigenesis in xenograft model
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CDC2, CDC20, CDCA7, and MCM7) or anti-apoptosis 
(AREG, PDCD6IP, IER3, and LGALS3). In contrast, genes 
up-regulated by X2 gene have the opposite function like 
anti-proliferation (MEF2C, NDRG1, and IGFBP3) or pro-
apoptosis (CASP1, PLA2G2A, and PLA2G6) [Fig 3]. 
 
Discussion
Alteration of HBV X gene has been closely associated 
with HCC pathogenesis. The mechanism of HBx in HCC 
development remains unclear. In this study, the C-terminal 
truncated HBx was frequently detected in HCC tissues 
(79.3%, n=111), which could also be confirmed by PCR 
with five pairs of primers encompassing the entire and 
different lengths of X gene. C-terminal truncated HBx, 
rather than the full-length HBx, could effectively transform 
normal liver cell lines and increase the tumourigenicity in 
cell models by a series of in vivo and in vitro experiments. 
 HBx plays an important role in HCC pathogenesis 
by interacting with cellular oncogenes and its functional 
domain involved in oncogenesis is at the middle of HBx 
protein. HBx can also induce apoptosis.3 In the present 
study, the apoptotic frequency was significantly higher 
in X2-expression cells than in X1-expression and mock 
control cells (P<0.001). The induction of apoptosis by the 
full-length HBx, but not by the C-terminal truncated HBx, 
strongly suggests the C-terminal peptide is required for 
HBx pro-apoptotic function. 
 Based on our observations, there are two important 
functional domains located within the full-length HBx. 
One is an oncogenic domain (the N-terminal through 
middle peptide) and the other is a pro-apoptotic domain 
(the C-terminal peptide). During infection, HBV survival 
is probably related to a balance between these two 
functions. When the pro-apoptotic domain is lost, which is 
probably through viral integration, the balance is broken. 
Subsequently, the dominant oncogenic domain accelerates 
the development of HCC. 
 The hypothesis of two functional domains of HBx protein 
was supported by our cDNA microarray results, although 
the molecular mechanism underlining the truncation of 
C-terminal HBx has yet to be determined. Consistent with 
the two-domain hypothesis, cDNA array revealed five 
genes with known functions of promoting cell proliferation 
were up-regulated in X1-expression cells, and three genes 
with known negative functions on cell proliferation were 
down-regulated at least two fold. These results suggest that 
Fig 3. A proposed model for the role of C-terminal truncated hepatitis B X protein (HBx) in hepatocellular carcinogenesis
C-terminal truncated HBx caused by hepatitis B virus (HBV) integration can promote cell proliferation and inhibit cell apoptosis
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the tumourigenic role of the C-terminal truncated HBx is 
via the activation of cell proliferation and inhibition of cell 
apoptosis (Fig 3). Our molecular dissections of the two-
domain peptides and functions are in progress.
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